The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II study of the anti-TGF-β monoclonal antibody (mAb) NIS793 with and without the PD-1 inhibitor spartalizumab in combination with nab-paclitaxel/gemcitabine (NG) versus NG alone in patients (pts) with first-line metastatic pancreatic ductal adenocarcinoma (mPDAC).
 
Peter Grell
No Relationships to Disclose
 
Chia-Chi Lin
No Relationships to Disclose
 
Michele Milella
No Relationships to Disclose
 
Cheng Ean Chee
No Relationships to Disclose
 
Shivan Sivakumar
No Relationships to Disclose
 
Katriina Johanna Peltola
No Relationships to Disclose
 
Geraldine Bostel
No Relationships to Disclose
 
Dragana Jankovic
No Relationships to Disclose
 
Maria-Athina Altzerinakou
No Relationships to Disclose
 
Claire Fabre
No Relationships to Disclose
 
Armando Santoro
No Relationships to Disclose